S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:BDTX

Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis

$5.07
+0.17 (+3.47%)
(As of 03/28/2024 ET)
Today's Range
$4.99
$5.27
50-Day Range
$2.67
$5.74
52-Week Range
$1.43
$6.85
Volume
353,642 shs
Average Volume
602,701 shs
Market Capitalization
$262.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.75

Black Diamond Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
112.0% Upside
$10.75 Price Target
Short Interest
Healthy
3.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.23mentions of Black Diamond Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.76) to ($1.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.45 out of 5 stars

Medical Sector

536th out of 938 stocks

Biological Products, Except Diagnostic Industry

90th out of 149 stocks

BDTX stock logo

About Black Diamond Therapeutics Stock (NASDAQ:BDTX)

Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

BDTX Stock Price History

BDTX Stock News Headlines

Make This $3 Trade the Instant the Opening Bell Rings
Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…
BDTX Black Diamond Therapeutics, Inc.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Black Diamond Therapeutics Inc (BDTX)
Black Diamond Therapeutics Inc.
Solitario: Q3 Earnings Snapshot
Black Diamond Therapeutics Inc Ordinary Shares BDTX
Black Diamond Therapeutics (BDTX) Receives a Buy from Piper Sandler
Co-founder of cancer biotech Black Diamond replaced as CEO
See More Headlines
Receive BDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2023
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BDTX
Web
N/A
Fax
N/A
Employees
54
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.75
High Stock Price Target
$12.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+110.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-82,440,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.26 per share

Miscellaneous

Free Float
47,027,000
Market Cap
$264.29 million
Optionable
Optionable
Beta
2.65
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Mark A. Velleca M.D. (Age 60)
    Ph.D., CEO, President & Chairman
    Comp: $43.89k
  • Dr. David M. Epstein Ph.D. (Age 65)
    Co-Founder & Director
    Comp: $885.08k
  • Dr. Fang Ni Pharm.D. (Age 37)
    CFO, Principal Financial Officer and Chief Business Officer
    Comp: $656.33k
  • Mr. Brent Hatzis-Schoch Esq.Mr. Brent Hatzis-Schoch Esq. (Age 59)
    J.D., COO & General Counsel
    Comp: $683.29k
  • Dr. Elizabeth Buck Ph.D. (Age 49)
    Co-Founder & Chief Scientific Officer
    Comp: $340.47k
  • Ms. Erika Jones (Age 39)
    VP of Finance, Corporate Controller & Principal Accounting Officer
  • Ms. Elizabeth L. Montgomery (Age 52)
    Chief People Officer
  • Dr. Sergey Yurasov M.D. (Age 55)
    Ph.D., Chief Medical Officer
  • Ms. Melanie Morrison
    Chief Development Officer

BDTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Black Diamond Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Black Diamond Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BDTX shares.
View BDTX analyst ratings
or view top-rated stocks.

What is Black Diamond Therapeutics' stock price target for 2024?

4 brokers have issued 1 year price targets for Black Diamond Therapeutics' stock. Their BDTX share price targets range from $10.00 to $12.00. On average, they anticipate the company's share price to reach $10.75 in the next year. This suggests a possible upside of 112.0% from the stock's current price.
View analysts price targets for BDTX
or view top-rated stocks among Wall Street analysts.

How have BDTX shares performed in 2024?

Black Diamond Therapeutics' stock was trading at $2.81 at the beginning of the year. Since then, BDTX shares have increased by 80.4% and is now trading at $5.07.
View the best growth stocks for 2024 here
.

When is Black Diamond Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our BDTX earnings forecast
.

How were Black Diamond Therapeutics' earnings last quarter?

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) posted its earnings results on Friday, August, 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.02.

What other stocks do shareholders of Black Diamond Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Black Diamond Therapeutics investors own include Alector (ALEC), Alteryx (AYX), Editas Medicine (EDIT), Gossamer Bio (GOSS), Micron Technology (MU), NVIDIA (NVDA), Homology Medicines (FIXX), II-VI (IIVI), Intel (INTC) and Invitae (NVTA).

When did Black Diamond Therapeutics IPO?

Black Diamond Therapeutics (BDTX) raised $151 million in an initial public offering on Thursday, January 30th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are Black Diamond Therapeutics' major shareholders?

Black Diamond Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Bellevue Group AG (16.53%), Vanguard Group Inc. (3.77%), Vanguard Group Inc. (3.77%), Verition Fund Management LLC (3.01%), Blue Owl Capital Holdings LP (1.35%) and Newtyn Management LLC (0.54%). Insiders that own company stock include Ali Behbahani, Brent Hatzis-Schoch, Christopher D Roberts, David M Epstein, Fang Ni and Growth N V Biotech.
View institutional ownership trends
.

How do I buy shares of Black Diamond Therapeutics?

Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BDTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners